PART I Item 1. B usiness. Overview We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. Haduvio acts on the cough reflex arc both centrally and periphe...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-110783 | EDGAR | 99K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-041194 | EDGAR | 100K words |
| 2024-03-20 | 2023-12-31 | 0000950170-24-034167 | EDGAR | 105K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008472 | EDGAR | 103K words |
| 2022-03-17 | 2021-12-31 | 0001564590-22-010875 | EDGAR | 103K words |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015506 | EDGAR | 106K words |
| 2020-03-16 | 2019-12-31 | 0001564590-20-010996 | EDGAR | 103K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-338023 | EDGAR | 23K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-280166 | EDGAR | 70K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105066 | EDGAR | 70K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067011 | EDGAR | 66K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122355 | EDGAR | 69K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093983 | EDGAR | 69K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054489 | EDGAR | 67K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062063 | EDGAR | 72K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041318 | EDGAR | 73K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021240 | EDGAR | 70K words |
| 2022-11-10 | 2022-09-30 | 0001564590-22-037385 | EDGAR | 73K words |
| 2022-08-11 | 2022-06-30 | 0001564590-22-029142 | EDGAR | 71K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-337974 | EDGAR | 2K words |
| 2026-03-17 | 0001193125-26-110767 | EDGAR | 2K words |
| 2026-03-09 | 0001193125-26-098676 | EDGAR | 1K words |
| 2025-12-05 | 0001193125-25-308769 | EDGAR | 1K words |
| 2025-11-13 | 0001193125-25-280149 | EDGAR | 2K words |
| 2025-08-20 | 0001563880-25-000005 | EDGAR | 1K words |
| 2025-08-07 | 0000950170-25-105011 | EDGAR | 2K words |
| 2025-06-17 | 0000950170-25-087486 | EDGAR | 1K words |
| 2025-06-04 | 0001193125-25-134913 | EDGAR | 1K words |
| 2025-06-02 | 0001193125-25-133273 | EDGAR | 1K words |
130 total filings indexed. 101 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001563880 |
| Ticker | TRVI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.trevitherapeutics.com |
| Listed | 2019-05-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TRVI (~200 tokens, structured JSON with cryptographic provenance)